Bangladesh vs Egypt: Share of the population living with HIV receiving antiretroviral therapy
Bangladesh
41.4%
in 2024
Egypt
44.7%
in 2024
Bangladesh rank
137th
Egypt rank
134th
Share of the population living with HIV receiving antiretroviral therapy over time
- Bangladesh
- Egypt
How they compare
Egypt currently reports 44.7% against 41.4% in Bangladesh, a difference of 3.3%.
That makes Egypt's figure about 1.1 times Bangladesh's.
The two have swapped places 6 times across 35 shared years of data; in 1990 it was Egypt ahead.
Bangladesh ranks 137th and Egypt ranks 134th of 149 countries.
Bangladesh has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Bangladesh | Egypt | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | — |
| 2000s | 1.2% | 0.6% | 0.6% | Bangladesh |
| 2010s | 14.2% | 9.9% | 4.3% | Bangladesh |
| 2020s | 34.5% | 34.2% | 0.2% | Bangladesh |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Bangladesh or Egypt?
- Egypt, at 44.7% against 41.4% in Bangladesh as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Bangladesh and Egypt?
- 3.3%, with Egypt ahead.
- How many years of comparable data are there for Bangladesh and Egypt?
- 35 years are reported by both, from 1990 to 2024.
- How do Bangladesh and Egypt rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Bangladesh ranks 137th and Egypt ranks 134th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.